What effect does thiopental have on the CO2 responsiveness of the cerebral vasculature?

What effect does thiopental have on the CO2 responsiveness of the cerebral vasculature?

• A. Thiopental attenuates the effect of hypocarbia on CBF
• B. Thiopental attenuates the effect of hypercarbia on CBF
• C. Thiopental augments the effect of hypercarbia on CBF
• D. Does not affect CO2 reactivity at a dose used clinically

Answer: (D)

CO2 reactivity refers to cerebral vessels’ ability to dilate when CO2 rises (hypercarbia) and constrict when CO2 falls (hypocarbia). Thiopental lowers the brain’s metabolic rate and cerebral blood flow, which helps reduce intracranial pressure, by causing overall cerebral vasoconstriction and reduced neuronal activity. But at doses used clinically, it does not blunt the vessels’ ability to respond to CO2 changes. In other words, the relationship between CO2 levels and cerebral blood flow remains functional: hypercarbia still increases CBF and hypocarbia still decreases it, even with thiopental. This preservation of CO2 reactivity contrasts with some other anesthetics (like certain volatile agents) that can dampen this response. So the effect is that thiopental does not affect CO2 reactivity at clinically used doses.

CO2 reactivity refers to cerebral vessels’ ability to dilate when CO2 rises (hypercarbia) and constrict when CO2 falls (hypocarbia). Thiopental lowers the brain’s metabolic rate and cerebral blood flow, which helps reduce intracranial pressure, by causing overall cerebral vasoconstriction and reduced neuronal activity. But at doses used clinically, it does not blunt the vessels’ ability to respond to CO2 changes. In other words, the relationship between CO2 levels and cerebral blood flow remains functional: hypercarbia still increases CBF and hypocarbia still decreases it, even with thiopental. This preservation of CO2 reactivity contrasts with some other anesthetics (like certain volatile agents) that can dampen this response. So the effect is that thiopental does not affect CO2 reactivity at clinically used doses.